Signed Dec 16, 2025 · Updated Jun 10, 2026
16 mapped awards newly signed in the last 12 months carry $2.93M in obligations (71% from Defense).
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
$0
Actual federal dollars obligated to date on this award
Not exposed by the award structure
A maximum, not earned revenue
$2.93M across 16 awards
Obligations to date on awards newly signed in the last 12 months, mapped to this company
71% from the largest awarding agency
Share of T12M mapped obligations
#16 of 16 mapped awards by obligations
Within the awards OQRO has ingested
0.00% of FY2022 revenue ($78.7B)
T12M mapped obligations ÷ revenue the company reported in its 10-K. A size comparison: obligations are not revenue and are usually earned over several years
verified alias
Exact identifier > verified alias > manual override
Congress tradeSits on House Ways and Means, Health5 different filers disclosed JNJ within 90 days. Disclosed 27 days after the transaction; reported as an official range, not an exact amount.
Derivative exercise or conversion — not an open-market buy.
124K → 114K shares held−8% of their stake
Johnson & Johnson's Chief TO and Risk Officer sold $2.41M of Johnson & Johnson shares. Nobody planned it ahead of time.
